2016 ATA Satellite Symposium: Clinical Guidelines on Management of Hyperthyroidism and Thyroid Illness During Pregnancy

The symposium entitled “2016 ATA Satellite Symposium: Clinical Guidelines on Management of Hyperthyroidism and Thyroid Illness During Pregnancy"  will feature two sessions based on the most recent recommendations from the interdisciplinary international guidelines task forces.

2016 ATA Guidelines: Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

Numerous studies since the publication of the 2011 guidelines have addressed the diagnosis and management of thyrotoxic patients. The ATA has developed new and updated evidence-based recommendations to guide the clinical assessment and management of patients with hyperthyroidism and other causes of thyrotoxicosis. Task force members will give special focus to:

  • New paradigms for establishing the etiology of thyrotoxicosis
  • Updated evidence for choosing treatment options for hyperthyroidism
  • Expanded coverage of less common causes of thyrotoxicosis

2016 ATA Guidelines: Thyroid Disease During Pregnancy 

Thyroid disease is common in pregnant women. The diagnosis and treatment of thyroid dysfunction in pregnancy provides unique challenges. A large amount of new information and evidence grading processes has become available since the 2011 guidelines prompting the ATA to develop new and updated evidence-based recommendations to assist in the clinical management of pregnant patients with thyroid disease. Task force members will give special focus to:

  • New definitions and treatment paradigms for hypothyroidism in pregnancy
  • Treatment of hyperthyroidism in pregnant women
  • Screening for thyroid dysfunction in pregnancy

Target Audience

This continuing medical education activity should be of substantial interest to the community of endocrinologists, internists, surgeons, basic scientists, nuclear medicine scientists, pathologists, trainees, nurses, physician assistants and other health care professionals who wish to broaden and update their knowledge on thyroid nodules, differentiated thyroid cancer and the current ATA guidelines surrounding these topics.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Describe the new paradigms in the 2016 ATA Guidelines on Hyperthyroidism for assessing the etiology of thyrotoxicosis, using TRAb measurements to assess the response to anti-thyroid drugs, and preparing patients for thyroid surgery.
  • Understand the risks and benefits of the three major treatment options for Graves’ hyperthyroidism—radioiodine, surgery and anti-thyroid drugs, including optimal choice of treatment in patients with orbitopathy
  • Appropriately diagnose and treat overt and subclinical thyrotoxicosis
  • Appropriately manage thyroiditis, other less common causes of thyrotoxicosis, and pediatric thyrotoxicosis
  • Describe major changes in the 2016 ATA Guidelines on Thyroid Disease in Pregnancy and how these should be applied in clinical practice
  • Understand how to interpret thyroid function changes in pregnant women
  • Appropriately diagnose, monitor, and treat Graves’ hyperthyroidism in pregnant women
  • Identify thresholds for treatment initiation and goals of therapy for women with hypothyroidism in pregnancy
  • Review considerations related to management of thyroid autoimmunity in pregnancy

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Quality Improvement and Healthcare Delivery
General Endocrinology
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credits
  • 4.50 CME Certificate of Participation
Course opens: 
Course expires: 
Boston, MA 02210
United States

Guidelines for the Management of Hyperthyroidism Faculty

Douglas S. Ross, MD, Chair
Massachusetts General Hospital, Boston, Massachusetts

Henry B. Burch, MD
Walter Reed National Military Medical Center, Bethesda, Maryland

David S. Cooper, MD
Johns Hopkins University School of Medicine, Baltimore, Maryland

Peter Laurberg, MD
Aalborg University Hospital Science and Innovation Centre, Aalborg, Denmark

Scott A. Rivkees, MD
University of Florida College of Medicine, Gainesville, Florida

Julie Ann Sosa, MD, MA, FACS
Duke University School of Medicine, Durham, North Carolina

Martin A. Walter, MD
University Hospital, Basel, Switzerland

Guidelines for the Management of Thyroid Illness during Pregnancy Faculty

Erik K. Alexander, MD, Co-Chair
Brigham and Women’s Hospital, Boston, Massachusetts

Elizabeth N. Pearce, MD, Co-Chair
Boston University Medical Center, Boston, Massachusetts

Gregory A. Brent, MD
VA Great Lost Angeles Healthcare System/ University of California, Los Angeles, Los Angeles, California

Herbert Chen, MD, FACS
University of Alabama School of Medicine, Birmingham, Alabama

Chrysoula Dosiou, MD, MS
Stanford University School of Medicine, Stanford, California

Peter Laurberg, MD
Aalborg University Hospital Science and Innovation Centre, Aalborg, Denmark

Susan J. Mandel, MD
University of Pennsylvania, Philadelphia, Pennsylvania

Robin P. Peeters, MD, PhD
Erasmus University Medical Center, Rotterdam, The Netherlands


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported no relevant financial relationship(s) during the content development process for this activity: Erik Alexander, MD; Gregory A. Brent, MD; Henry Burch, MD; Herb Chen, MD; David Cooper, MD; Chrysoula Dosiou, MD; Peter Laurberg, MD; Susan Mandel, MD; Elizabeth Pearce, MD; Robin Peeters, MD; Scott Rivkees, MD; Douglas Ross, MD; Julie Ann Sosa, MD; Martin Walter, MD

The following Endocrine Society Special Programs Committee (SPC) member who reviewed content for this activity reported no relevant financial relationships:  Larry Fox, MD

The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Alan Kelly, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society and ATA staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 4.50 AMA PRA Category 1 Credits
  • 4.50 CME Certificate of Participation